“Drug Repurposing in Cholangiocarcinoma” by Professor Rutaiwan Tohtong Department of Biochemistry, Faculty of Science Mahidol University Date: July 1, 2026 Time: 11:00 am Venue: B301
Tag: RT
Association of a CD44s-v5-v6 Null Phenotype with Advanced Stage Cholangiocarcinoma: A Preliminary Study
Cholangiocarcinoma is a very aggressive bile duct cancer with poor survival rates, making it crucial for doctors to better predict patient outcomes. Scientists have long
Stability of Bioactive Compounds and Wound Healing Activities of Porcine Placental Extract
Porcine placental extract (PPE) is a biologically active substance enriched with proteins and regenerative mediators, offering therapeutic potential in wound healing applications. However, the long-term
The Stimulatory Effect of Porcine Placenta Extract on in vitro Biological Activities of Keratinocytes and Fibroblasts
Porcine placenta extract (PPE), a synergistic bioactive compound, enhances cellular functions such as proliferation, migration, and cellular signaling. Keratinocytes and fibroblasts play essential roles during
Identification of transcriptional regulators of immune evasion across cancers: an alternative immunotherapeutic strategy for cholangiocarcinoma
Current immunotherapies are ineffectively designed toward single-target inhibition in a complex multifactored process. Moreover, available therapeutics are incapable of meeting the needs of the expanding
BC Faculty Seminar: May 1, 2024
“Therapeutic Implications of Ceritinib in Cholangiocarcinoma beyond ALK Expression and Mutation” by Professor Dr. Rutaiwan Tohtong Department of Biochemistry, Faculty of Science Mahidol University Time:
Therapeutic Implications of Ceritinib in Cholangiocarcinoma beyond ALK Expression and Mutation
Cholangiocarcinoma (CCA) is a difficult-to-treat cancer, with limited therapeutic options and surgery being the only curative treatment. Standard chemotherapy involves gemcitabine-based therapies combined with cisplatin,
Targeting MYC at the intersection between cancer metabolism and oncoimmunology
MYC activation is a known hallmark of cancer as it governs the gene targets involved in various facets of cancer progression. Of interest, MYC
Preclinical evidence for anaplastic lymphoma kinase inhibitors as novel therapeutic treatments for cholangiocarcinoma
Introduction: Bile duct cancer (cholangiocarcinoma, CCA) has a poor prognosis for patients, and despite recent advances in targeted therapies for other cancer types, it is still
Upregulated LAMA3 modulates proliferation, adhesion, migration and epithelial‑to‑mesenchymal transition of cholangiocarcinoma cells
Cholangiocarcinoma (CCA), a bile duct cancer, is an aggressive cancer with poor prognosis. It is typically recognized by its dense extracellular matrix nature which associated